Article ; Online: Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2024 Volume 38, Issue 2, Page(s) 177–203
Abstract: The last decade (2013-2023) has seen unprecedented successes in the clinical translation of therapeutic antisense oligonucleotides (ASOs). Eight such molecules have been granted marketing approval by the United States Food and Drug Administration (US FDA) ...
| Abstract | The last decade (2013-2023) has seen unprecedented successes in the clinical translation of therapeutic antisense oligonucleotides (ASOs). Eight such molecules have been granted marketing approval by the United States Food and Drug Administration (US FDA) during the decade, after the first ASO drug, fomivirsen, was approved much earlier, in 1998. Splice-modulating ASOs have also been developed for the therapy of inborn errors of metabolism (IEMs), due to their ability to redirect aberrant splicing caused by mutations, thus recovering the expression of normal transcripts, and correcting the deficiency of functional proteins. The feasibility of treating IEM patients with splice-switching ASOs has been supported by FDA permission (2018) of the first "N-of-1" study of milasen, an investigational ASO drug for Batten disease. Although for IEM, owing to the rarity of individual disease and/or pathogenic mutation, only a low number of patients may be treated by ASOs that specifically suppress the aberrant splicing pattern of mutant precursor mRNA (pre-mRNA), splice-switching ASOs represent superior individualized molecular therapeutics for IEM. In this work, we first summarize the ASO technology with respect to its mechanisms of action, chemical modifications of nucleotides, and rational design of modified oligonucleotides; following that, we precisely provide a review of the current understanding of developing splice-modulating ASO-based therapeutics for IEM. In the concluding section, we suggest potential ways to improve and/or optimize the development of ASOs targeting IEM. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Metabolic Diseases/drug therapy ; Metabolic Diseases/genetics ; Oligonucleotides, Antisense/therapeutic use ; United States | |||||
| Chemical Substances | Oligonucleotides, Antisense | |||||
| Language | English | |||||
| Publishing date | 2024-01-22 | |||||
| Publishing country | New Zealand | |||||
| Document type | Review ; Journal Article | |||||
| ZDB-ID | 1364202-9 | |||||
| ISSN | 1179-190X ; 1173-8804 | |||||
| ISSN (online) | 1179-190X | |||||
| ISSN | 1173-8804 | |||||
| DOI | 10.1007/s40259-024-00644-7 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4112: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.